Literature DB >> 21605046

Mechanisms of tau self-aggregation and neurotoxicity.

G Farías1, A Cornejo, J Jiménez, L Guzmán, R B Maccioni.   

Abstract

Pathological tau protein aggregates can be found in brain of patients with some of the neurodegenerative diseases collectively known as tauopathies, which include Alzheimer's disease (AD). Since tau post-translational modifications including phosphorylations, glycosylations, truncation and the subsequent aggregation in oligomers, paired helical filaments (PHFs) and neurofibrillary tangles (NFTs), correlate with cognitive impairment and neurodegeneration in AD, a pathogenic role for tau and its modifications has been raised. Here we summarize the current status of knowledge about tau modifications under pathologic conditions and the evidence supporting neurotoxic - or neuroprotective - roles of the diverse forms of modified and aggregated tau. Finally, we analyze the structural and functional tau alterations found in different tauopathies and how these modifications are related to the pathophysiologic mechanisms of neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21605046     DOI: 10.2174/156720511796717258

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  20 in total

Review 1.  Physicochemical properties of cells and their effects on intrinsically disordered proteins (IDPs).

Authors:  Francois-Xavier Theillet; Andres Binolfi; Tamara Frembgen-Kesner; Karan Hingorani; Mohona Sarkar; Ciara Kyne; Conggang Li; Peter B Crowley; Lila Gierasch; Gary J Pielak; Adrian H Elcock; Anne Gershenson; Philipp Selenko
Journal:  Chem Rev       Date:  2014-06-05       Impact factor: 60.622

Review 2.  Molecular mechanisms of developmental pathways in neurological disorders: a pharmacological and therapeutic review.

Authors:  Niraj Kumar Jha; Wei-Chih Chen; Sanjay Kumar; Rajni Dubey; Lung-Wen Tsai; Rohan Kar; Saurabh Kumar Jha; Piyush Kumar Gupta; Ankur Sharma; Rohit Gundamaraju; Kumud Pant; Shalini Mani; Sandeep Kumar Singh; Ricardo B Maccioni; Tirtharaj Datta; Sachin Kumar Singh; Gaurav Gupta; Parteek Prasher; Kamal Dua; Abhijit Dey; Charu Sharma; Yasir Hayat Mughal; Janne Ruokolainen; Kavindra Kumar Kesari; Shreesh Ojha
Journal:  Open Biol       Date:  2022-03-16       Impact factor: 6.411

3.  Flavonoid Derivatives as Potential Cholinesterase Inhibitors in Scopolamine-Induced Amnesic Mice: An In Vitro, In Vivo and Integrated Computational Approach.

Authors:  Fakhria A Al-Joufi; Syed Wadood Ali Shah; Mohammad Shoaib; Mehreen Ghias; Atif Ali Khan Khalil; Syed Babar Jamal; Syed Muhammad Hassan Shah; Muhammad Zahoor
Journal:  Brain Sci       Date:  2022-06-02

Review 4.  Molecular signaling pathway targeted therapeutic potential of thymoquinone in Alzheimer's disease.

Authors:  Fabiha Zaheen Khan; Md Shaki Mostaid; Mohd Nazmul Hasan Apu
Journal:  Heliyon       Date:  2022-07-05

5.  When amyloids become prions.

Authors:  Raimon Sabate
Journal:  Prion       Date:  2014-05-15       Impact factor: 3.931

6.  Amyloid Beta and tau proteins as therapeutic targets for Alzheimer's disease treatment: rethinking the current strategy.

Authors:  Siddhartha Mondragón-Rodríguez; George Perry; Xiongwei Zhu; Jannic Boehm
Journal:  Int J Alzheimers Dis       Date:  2012-03-08

7.  Amyloid-β Peptides and Tau Protein as Biomarkers in Cerebrospinal and Interstitial Fluid Following Traumatic Brain Injury: A Review of Experimental and Clinical Studies.

Authors:  Parmenion P Tsitsopoulos; Niklas Marklund
Journal:  Front Neurol       Date:  2013-06-26       Impact factor: 4.003

8.  Will posttranslational modifications of brain proteins provide novel serological markers for dementias?

Authors:  Y Wang; M G Sørensen; Q Zheng; C Zhang; M A Karsdal; K Henriksen
Journal:  Int J Alzheimers Dis       Date:  2012-06-21

9.  Glycogen synthase kinase 3: a point of integration in Alzheimer's disease and a therapeutic target?

Authors:  Siddhartha Mondragón-Rodríguez; George Perry; Xiongwei Zhu; Paula I Moreira; Sylvain Williams
Journal:  Int J Alzheimers Dis       Date:  2012-06-14

10.  GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease.

Authors:  Carlos Cruchaga; John S K Kauwe; Oscar Harari; Sheng Chih Jin; Yefei Cai; Celeste M Karch; Bruno A Benitez; Amanda T Jeng; Tara Skorupa; David Carrell; Sarah Bertelsen; Matthew Bailey; David McKean; Joshua M Shulman; Philip L De Jager; Lori Chibnik; David A Bennett; Steve E Arnold; Denise Harold; Rebecca Sims; Amy Gerrish; Julie Williams; Vivianna M Van Deerlin; Virginia M-Y Lee; Leslie M Shaw; John Q Trojanowski; Jonathan L Haines; Richard Mayeux; Margaret A Pericak-Vance; Lindsay A Farrer; Gerard D Schellenberg; Elaine R Peskind; Douglas Galasko; Anne M Fagan; David M Holtzman; John C Morris; Alison M Goate
Journal:  Neuron       Date:  2013-04-04       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.